NEWS | BEAM Alliance


BioVersys announces a EUR 6.92 Million funding of its TRIC-TB project by the IMI2 JU and extends its successful collaboration with long term partners

Basel, Switzerland, June 20, 2019. 13:00 CET 

BioVersys has been awarded EUR 6.92 Million funding for TRIC-TB from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853800. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

BioVersys is pleased to announce that it has received an IMI2 JU grant of 6.92 million EUR to fund further preclinical through to first clinical development of candidate molecules from the TRIC-TB project which have been developed in a successful collaboration with GSK, the Institut Pasteur de Lille and University of Lille (with groups of Nicolas Willand, Alain Baulard and Benoit Deprez). The project previously received valuable financial support from the Wellcome Trust.

Full PR available here